Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly Parkinson's disease.
SynuCa Therapeutics has raised $1.5M in total funding. The most recent round was Seed. The last funding was announced in March 2026.
SynuCa Therapeutics's investors include BioInnovation Institute Venture Lab.
SynuCa Therapeutics is headquartered in Aarhus, Denmark.
Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly Parkinson's disease.
SynuCa Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SynuCa Therapeutics — Funding & Investors." VCBacked, March 2, 2026, https://www.vcbacked.co/company/synuca-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). SynuCa Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/synuca-therapeutics
{{cite web |title=SynuCa Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/synuca-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated